Category:

South Africa

• • •

• • •

Mosa Meat Becomes B Corp Certified

Cultivated meat pioneer joins the global community of businesses that meet high standards of social and environmental impact. Maastricht, Netherlands, Sept. 07, 2023 (GLOBE NEWSWIRE) — Mosa Meat, a leader in cultivated beef production, announced today to have become a Certified B Corporation™. This marks a significant milestone in the

• • • Read More • • •

Resonac Partners with Matmerize to Pioneer 6G Technology Advancement using Innovative AI Software

ATLANTA, Sept. 06, 2023 (GLOBE NEWSWIRE) — In a significant collaboration, Matmerize, Inc., a materials AI innovator, and Resonac Corporation have formed a strategic partnership aimed at revolutionizing the landscape of 6G technology. Building on the strong collaborative foundation, Resonac will leverage the power of Matmerize’s PolymRize™ AI software technology

• • • Read More • • •

eLichens is introducing the first Natural Gas Detector integrating NB-IoT/LTE-M Connectivity from Sequans

Avolta Natural Gas Detector with NB-IoT/LTE-M Connectivity GRENOBLE, France, Sept. 05, 2023 (GLOBE NEWSWIRE) — eLichens, a leading provider of non-dispersive infrared sensors and detectors, is thrilled to announce the collaboration with Sequans, resulting in the latest evolution of its Avolta, Natural Gas Detector (NGD). This new edition of Avolta

• • • Read More • • •

Zoom introduces Zoom AI Companion — available at no additional cost with paid Zoom user accounts

New generative AI-powered assistant helps improve collaboration and productivity SAN JOSE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) — Today, Zoom Video Communications, Inc. (NASDAQ: ZM) announced that Zoom AI Companion (formerly Zoom IQ), the company’s generative AI digital assistant, is now included at no additional cost for customers with the

• • • Read More • • •

Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia

Collaboration furthers Zenas’ vision to bring innovative immunology-based medicines to patients around the world by leveraging Bristol Myers Squibb’s long-standing expertise in immune-mediated diseases Zenas will receive a $50 million up-front cash payment and an equity investment from Bristol Myers Squibb, along with additional potential milestone-based payments and royalties in

• • • Read More • • •

RECENT POSTS